Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
About this item
Full title
Author / Creator
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Purpose of Review
The moderate glucose-lowering effect of sodium glucose co-transporter 2 (SGLT2) inhibitors is unlikely to explain SGLT2 inhibitor-mediated beneficial outcomes, and unravelling the underlying mechanisms is a high priority in the research community. Given the dominant pathophysiologic role of the sympathetic nervous system activa...
Alternative Titles
Full title
Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8942945
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8942945
Other Identifiers
ISSN
1522-6417
E-ISSN
1534-3111
DOI
10.1007/s11906-022-01170-z
